echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > In the fifth round of national mining, these 79 varieties may be selected!

    In the fifth round of national mining, these 79 varieties may be selected!

    • Last Update: 2021-07-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to the latest review of Fengyun Pharmaceutical Talk
    , the
      fifth round of national procurement by the medical network
    , as of March 1, 2021, the varieties that have passed the consistency evaluation but have not yet been collected (according to the common name) ) A total of 281 varieties, of which 79 varieties have passed the consistency evaluation of 3 (≥1+2 pattern), 100 varieties have passed the uniformity evaluation, and only 102 varieties have been evaluated by one pharmaceutical company (general Name)

    .
    According to the past analysis, the fifth batch of national procurement is expected to be launched in June, and quotations may begin in August

    .
    According to Cyber ​​Blue, from the first round of 4+7 procurement to 4+7 expansion, to the second and third rounds of national centralized procurement, we can see that the timing of centralized procurement has begun to emerge-the first round of 4 +7 The results of centralized procurement will be released in December 2018, and will be implemented from February to February of the following year; six months later, the procurement of the first batch of 25 varieties will be expanded to the whole country; the second round of centralized procurement, the results will be released in January 2020, 4 May has entered the procurement stage; the third round of centralized procurement, the centralized procurement documents will be released on July 29, 2020, the official announcement of the official selection results on August 24, and the results of centralized procurement in many places across the country in November; the fourth round of centralized procurement, On December 25, 2020, the Shanghai Sunshine Pharmaceutical Purchasing website officially announced that on February 8, 2021, the final selection results of the fourth batch of national sources will be announced.
    According to official sources, the fourth batch of national sources is expected to land in May

    .
    From the third and fourth batches of national procurement, it can be seen that it takes about half a year from the confirmation of the variety to the implementation of the results of the national procurement.
    It seems that if no surprises, the new batch of national procurement is expected to start in June.
    , Landed a year ago

    .
    Recently, a document concerning the main points of medical insurance work in 2021 has flowed out.
    The main points of the work are clear.
    Follow-up related departments will normalize and institutionalize the centralized procurement of pharmaceutical consumables and promote the fourth and fifth batches of national organization of centralized drug procurement

    .
    The state organizes the normal operation of centralized drug procurement, and the progress of two batches a year is clear

    .
    According to the previous law of centralized procurement, after the previous batch of centralized procurement is launched, a new round of centralized procurement may begin.

    .
    Recently, multi-provincial recruitment platforms have successively released documents on the results of the fourth batch of national procurement

    .
    Among them, Liaoning Province has made it clear that from May 1, 2021, the fourth batch of nationally selected varieties can be purchased online .
    It is not difficult to see that with the landing of the fourth batch of national mining companies, the pace of the fifth batch of national mining companies is getting closer

    .
    It is worth noting that the Fengyun Medicine Talks pointed out that with the acceleration of the consistency evaluation of generic drugs, by the time the fifth batch of national procurement reports, there may be 100 varieties that meet the requirements of centralized procurement.
    Maturity and the accumulation of experience of enterprises participating in centralized procurement, and the acceleration of centralized procurement is also a high probability event

    .

      Injections may welcome price cuts.

    It is worth noting that among the 79 varieties that meet the requirements for national procurement so far, 34 injections are available

    .
    (Information source: NMPA catalog collection Insight Fengyun medicine talks exclusive collation) Reviewing the introduction of the injections in the first four rounds of national procurement, you can see: The first round of 4+7 purchases: flurbiprofen axetil injection, Peimer for injection The
      second batch of troxe disodium and dexmedetomidine hydrochloride injection
    are purchased in quantity: paclitaxel for injection (albumin-bound type) and the
    third batch: azacitidine for injection, levetiracetam injection concentrated solution, Moxifloxacin Hydrochloride and Sodium Chloride Injection, the fourth batch: doxofylline injection, ibuprofen injection, ambroxol injection, propofol medium and long chain fat emulsion, parecoxib injection, pantoprazole Injection, bortezomib injection and bivalrudine for injection

    .
    According to Cyber ​​Blue, a total of 15 injections have been included in the current four batches of national procurement, and with the acceleration of injection consistency evaluation, the number of injections that have been adopted has increased significantly

    .
    Prior to this, relevant conversational information has been released, which will gradually increase the proportion of injections in the national centralized procurement.

    .
    It is worth noting that at present, injections are already a popular variety for mass procurement in many provinces, inter-provincial alliances, and city-level alliances.
    Specifically, although the disease distribution fields of the varieties selected by provinces are not the same, in general, , Antibiotics accounted for the highest proportion, injections also accounted for the highest proportion

    .
    According to data from Mi Nei.
    com, the overall scale of terminal chemical drugs in China's public medical institutions exceeded RMB 100 billion in 2019, of which injections accounted for nearly 60%

    .
    Some analysts pointed out that with the advancement of the consistency evaluation of injections, more and more injections will be included in the centralized procurement in the future, and the price of injections will be surging

    .
    Take the fourth batch of national procurement as an example.
    In 2019, the
    income of the sample
    hospitals accounted for more than 30% of the income of the total sample hospitals of 45 varieties, and the income of the sample hospitals accounted for more than 30% of the total sample hospitals’ income.
    The market size of doxofylline has shrunk the most after winning the bid, with drops as high as 97.
    9%, 98.
    8% and 86.
    3%

    .
    It can be seen that, due to the large market share of the injections adopted by the fourth batch of countries and the large number of competing companies, it eventually led to a higher price drop

    .
    As for the competition of the fifth batch of injections produced by countries, let us wait and see

    .

      What about the five rounds of national procurement rules?
    According to Cyber ​​Blue, the rules for the four rounds of centralized procurement so far are as follows: The first round of 4+7 centralized procurement: 11 pilot cities, 25 varieties, and a 12-month
    procurement cycle.
    Only the lowest price company is allowed to be selected

    .
    4+7 expansion: covering 25 alliance regions, allowing up to 3 companies to choose to share 70% of the agreed purchase volume (1 50%, 2 60%), and the purchase cycle is up to 2 years (may be extended by one depending on the situation) Years, ie 3 years in total)

    .
    The second round of centralized procurement: national participation, 32 varieties, and a maximum of 6 companies are allowed to be selected.
    The procurement cycle of varieties selected by 4 or more companies is 3 years (1 for 1 year, 2 or 3 for 2 years), 4 80% of the agreed-upon purchases shared among the above-selected companies (50% for one company, 60% for two companies, and 70% for three companies)

    .
    The third round of centralized procurement: national participation, 55 varieties, and a maximum of 8 pharmaceutical companies are allowed to choose.
    The procurement cycle of varieties selected by 4 or more companies is 3 years (1 or 2 companies, 1 year; 3 companies, 2 years; 4 and above, 3 years), 80% of the shared agreed procurement volume selected from 4 and above (50% for 1 company, 60% for 2 companies, and 70% for 3 companies)

    .
    The fourth round of centralized procurement: national participation, 45 varieties, and a maximum of 10 companies are allowed to be selected.
    The procurement cycle of varieties selected by 4 or more companies is 3 years (1 or 2 companies, 1 year; 3 companies, 2 years; 4 Home and above, 3 years), 80% of the shared agreed purchases among 4 and above (50% for 1 company, 60% for 2 companies, and 70% for 3 companies)

    .
    Satisfying one of the three conditions of a fuse mechanism of 1.
    8 times, a reduction of greater than or equal to 50%, and a unit comparable price of less than or equal to 0.
    1 yuan is still a condition for the enterprise to obtain the qualification for the proposed selection

    .
    On the whole, the relevant rules of the state organizing the centralized procurement of
    medicines have stabilized, and the adjustment of the rules based on the characteristics of some centralized procurement varieties is also a possible action
    .
    Looking back at the fourth round of national procurement, on the same day that the Shanghai Sunshine
    Pharmaceutical Procurement Network announced its launch, the Premier of the State Council presided over an executive meeting of the State Council to make arrangements to further promote the reform of centralized drug procurement
    .
    The meeting pointed out that centralized procurement should take into account the reasonable profits of the
    enterprise while reducing the burden on patients , and promote product innovation and upgrading
    .
    Some analysts pointed out that in terms of price cuts, the third round of centralized procurement hit a record high, and the fourth round of national procurement eased

    .
    In addition, in the fourth batch of centralized procurement, the success rate of corporate bidding increased

    .
    As for the fifth batch of national procurement, which may soon arrive, what kind of competition prelude will be opened is worth looking forward to

    .
    List of 79 varieties that meet the fifth round of national procurement (information source: NMPA catalog collection Insight Fengyun Yaotan exclusive collation)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.